Abstract
Immunological thrombocytopenia (ITP), immune neutropenia, and/or autoimmune haemolytic anaemia (AIHA) can develop concurrently or sequentially in Evans syndrome (ES), an uncommon illness. Frequent relapses, a heavy therapeutic load, and an elevated risk of infection and thrombosis are its hallmarks, all of which have a substantial impact on survival. Several illnesses, including as lymphoproliferative disorders, other systemic autoimmune diseases, and primary immunodeficiencies, can be categorized as primary or secondary to ES. The syndrome has a major influence on survival and quality of life and is frequently severe and sometimes fatal. Effective management of ES requires prompt therapy, including anti-infectious and anti-thrombotic prophylaxis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
